Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05576051 · ClinicalTrials.gov registry record
To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 9,159
- Enrollment target
NCT05576051 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 9,159 participants.
The verdict
NCT05576051 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 9,159 participants
- Enrollment target
Study Summary
To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.
Interventions
- OTHER patterns of use of combination therapy and monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,159 participants |
| Start Date | 2015-06-04 |
| Est. Completion | 2015-10-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05576051
The ClinicalTrials.gov registry entry for NCT05576051 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9,159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which patterns of use of combination therapy and monotherapy is the first listed.
NCT05576051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05576051 about?
NCT05576051 is a clinical study titled "To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.". To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.
What is the current status of trial NCT05576051?
This trial is currently completed. The enrollment target is 9,159 participants. The study started on 2015-06-04. Estimated completion is 2015-10-07.
What interventions are being tested in trial NCT05576051?
The interventions under investigation include: patterns of use of combination therapy and monotherapy (OTHER).
Who is sponsoring clinical trial NCT05576051?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.